Pharmachal and its Israeli collaboration partner Rambam Medtech are pleased to announce that approval has been granted to commence rabbit trials of the Peptide 16AC + "NOPAYNE" 3% lidocaine lipid nano particle (mini-emulsion) combination spray for rapid coagulation, local anaesthesia, and accelerated wound healing.
Trials are expected to run for 3 months, paving the way for fast-tracked human clinical trials in 2025.
Pharmachal's founder Charles Fridlender said, "The results from mouse trials were better than we could have possibly imagined. This next round of data will provide a better model for drug absorption, distribution, metabolism, toxicity and excretion, equipping us for the upcoming human clinical trials."
About Rambam Medtech
Rambam Medtech is part of the Rambam Health Care Campus, a 1100-bed academic hospital serving the over 2.5 million residents of Northern Israel. Providing comprehensive medical services in all medical specialties, Rambam is the tertiary referral centre for 12 district hospitals. Rambam's is committed to the entire spectrum of patient care, ranging from the best treatments and therapies to the support of clinical research.
Kommentarer